Understanding how a specific protein modification affects cancer development
Regulation of the ERK signaling pathway by K63-linked polyubiquitination
This study is looking at how a specific process in our cells affects important proteins that help control cell behavior, which could lead to better cancer treatments for patients by understanding how tumors grow and resist drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10903731 on NIH RePORTER |
What this research studies
This research investigates the role of K63-linked polyubiquitination in the activation of ERK1 and ERK2, proteins that are crucial for cell signaling and behavior. By exploring how this modification influences tumor growth and drug resistance, the study aims to uncover new therapeutic targets for various cancers. The approach involves detailed biochemical analyses and cellular experiments to understand the mechanisms at play. Patients may benefit from insights that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that exhibit hyperactivation of the ERK pathway or those who have experienced drug resistance in their treatment.
Not a fit: Patients with cancers not associated with the ERK signaling pathway may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target cancers driven by the ERK signaling pathway.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Xiaolu — University of Pennsylvania
- Study coordinator: Yang, Xiaolu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.